Anti-EGFR monoclonal antibodies which act as EGF, TGFα, HB-EGF and BTC antagonists block the binding of epiregulin to EGFR-expressing tumours

This publication has 17 references indexed in Scilit:

• Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tryosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4
  Oncogene, 1997
• Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation
  The EMBO Journal, 1997
• Epidermal Growth Factor-related Peptides Activate Distinct Subsets of ErbB Receptors and Differ in Their Biological Activities
  Journal of Biological Chemistry, 1996
• Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer
  British Journal of Cancer, 1996
• Type 1 growth factor receptors: an overview of recent developments
  The Breast, 1995
• Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research
  Breast Cancer Research and Treatment, 1995
• Immunotherapy with antibodies to the EGF receptor
  International Journal of Cancer, 1994
• The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468
  British Journal of Cancer, 1993
• The Physiology Of Transforming Growth Factor-α
  Advances in Cancer Research, 1992
• MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF
  Biochemical and Biophysical Research Communications, 1985